Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Replimune

Replimune
2015 FOUNDED
PUBLIC STATUS
61-70 EMPLOYEES
REPL STOCK SYMBOL
$13.97 SHARE PRICE (As of Monday Closing)
Description

Replimune Group Inc is a clinical-stage biotechnology company. Its use proprietary Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. The company's pipeline products include RP1, RP2, and RP3.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Stock Exchange
NAS
Primary Office
  • 18 Commerce Way
  • Woburn, MA 01801
  • United States

+1 (781) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Replimune’s full profile, request a free trial.

Replimune Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$8.88 - $23.55 $442M $13.12 -$1.33 43.4K 31.7M

Replimune Financials Summary

In Thousands,
USD
TTM
31-Mar-2019
FY 2019
31-Mar-2019
FY 2018
31-Mar-2018
FY 2017
31-Mar-2017
Enterprise Value 339,861 339,861
Revenue 0 0 0 0
EBITDA (33,271) (33,271) (19,881) (7,607)
Net Income (30,834) (30,834) (19,702) (7,704)
Total Assets 154,326 154,326 65,151 22,819
Total Debt 6,561 6,561 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Replimune Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Replimune‘s full profile, request access.

Request full access to PitchBook

Replimune Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Replimune‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Replimune Competitors (23)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aura Biosciences Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
000000000 00000000 Formerly VC-backed Emeryville, CA 000 00000 00000000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000000 00000
000000 00000000000 Failed Transaction (M&A) Cambridge, MA 000 00000 000000&0
000 0000000000000 Private Equity-Backed Saint Asaph, United Kingdom 00 000.00 0000000 0000 000.00
To view this company’s complete list of competitors, request access »

Replimune Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Replimune‘s full profile, request access.

Request full access to PitchBook

Replimune Executive Team (10)

Name Title Board
Seat
Contact
Info
Robert Coffin Ph.D Co-Founder, Chief Executive Officer & Board Member
Colin Love Chief Operating Officer
Tess Schmalbach Executive Medical Director
Pamela Esposito Chief Business Officer
Philip Astley-Sparke Co-Founder & Executive Chairman
You’re viewing 5 of 10 executives. Get the full list »

Replimune Board Members (10)

Name Representing Role Since Contact
Info
Hyam Levistsky Self Board Member 000 0000
Jason Rhodes Atlas Venture Board Member 000 0000
Joseph Slattery Self Board Member 000 0000
Kapil Dhingra MD Forbion Board Member & Special Advisor 000 0000
Michael Gladstone Atlas Venture Board Observer 000 0000

1 Former Board Member

You’re viewing 5 of 10 board members. Get the full list »